Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H20FN2O4S.Na |
Molecular Weight | 438.448 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4
InChI
InChIKey=JRBVAOJTPBHRQQ-XFULWGLBSA-M
InChI=1S/C21H21FN2O4S.Na/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26;/h1-6,8-9,15,23H,7,10-13H2,(H,25,26);/q;+1/p-1/t15-;/m1./s1
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C21H20FN2O4S |
Molecular Weight | 415.458 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ramatroban is a dual antagonist of thromboxane A2 receptor and PGD2 receptor. The drug was developed by Bayer and tested for the treatment of asthma and allergic rhinitis. In Japan ramatroban reached final approval and is being marketed under the name Baynas. In vitro studies have shown that the drug effectively inhibits smooth muscle cells contraction.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9296280
Curator's Comment: Ramatroban and its labeled metabolites did hardly penetrate the blood-brain barrier.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2069 |
10.0 nM [Ki] | ||
Target ID: CHEMBL5071 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15179446 |
30.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BAYNAS Approved UseTreatment of Allergic rhinitis. Launch Date2000 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
85 ng/mL |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
126.9 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
349.6 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
103.7 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
211.1 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
237.2 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
689.1 ng/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
209 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
265 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
320.9 ng/mL |
75 mg 2 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
302.5 ng/mL |
75 mg 2 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
518.1 ng/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
749.8 ng/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
404.5 ng/mL |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
457.9 ng/mL |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
137.4 ng × h/mL |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
193.6 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
555.2 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
422.9 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
972.8 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1284.9 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3214.8 ng × h/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
996.6 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
884.8 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1139.1 ng × h/mL |
75 mg 2 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1142.2 ng × h/mL |
75 mg 2 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1703.1 ng × h/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2099.4 ng × h/mL |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1188 ng × h/mL |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1220.3 ng × h/mL |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.93 h |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.79 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.95 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.21 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.03 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.33 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.45 h |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.17 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.52 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.63 h |
75 mg 2 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.13 h |
75 mg 2 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.54 h |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.31 h |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.34 h |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2.93 h |
50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAMATROBAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.95% |
RAMATROBAN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors. | 2002 Aug 9 |
|
Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. | 2005 Sep 16 |
|
Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats. | 2006 Nov |
|
Zwitterionic CRTh2 antagonists. | 2011 Mar 24 |
Patents
Sample Use Guides
75 mg is administered orally devided in two doses, after breakfast and after dinner (or before going to bed).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1839139
Human airway smooth muscle preparations and lung strips were treated wuth 10(-6), 10(-7) and 10(-8) M of remetroban to inhibit U46619-induced contractions.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:17 GMT 2025
by
admin
on
Mon Mar 31 17:59:17 GMT 2025
|
Record UNII |
5J3I129AXS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1040405-44-4
Created by
admin on Mon Mar 31 17:59:17 GMT 2025 , Edited by admin on Mon Mar 31 17:59:17 GMT 2025
|
PRIMARY | |||
|
67027609
Created by
admin on Mon Mar 31 17:59:17 GMT 2025 , Edited by admin on Mon Mar 31 17:59:17 GMT 2025
|
PRIMARY | |||
|
5J3I129AXS
Created by
admin on Mon Mar 31 17:59:17 GMT 2025 , Edited by admin on Mon Mar 31 17:59:17 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |